A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

169

Participants

Timeline

Start Date

June 26, 2023

Primary Completion Date

March 15, 2026

Study Completion Date

June 30, 2026

Conditions
Solid Tumor
Interventions
DRUG

ABSK121-NX

In the escalation part, patients will receive a single dose of oral ABSK121-NX on Day -7 followed by a 7-day washout (Day -7 dosing day as 1st day of wash out) as a run-in period to access the safety and PK of ABSK121-NX. Then, patients will continuously receive ABSK121-NX once daily (QD) starting at C1D1 and continuing in subsequent cycles (28-day cycles). The starting dose is 3mg QD. In the expansion part, patients will each receive oral ABSK121-NX at the RDE in repeated 28-day cycles.

Trial Locations (24)

44718

Gabrail Cancer Center Research, Canton

48201

Karmanos Cancer Institute, Detroit

89119

Comprehensive Cancer Centers of Nevada, Las Vegas

92093

UC San Diego Moores Cancer Center, La Jolla

Unknown

Chongqing University Cancer Hospital, Chongqing

The First Affiliated Hospital of Henan University of Science & Technology, Luoyang

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Hubei Cancer Hospital, Wuhan

Hunan Central Hospital, Changsha

The Affiliated Hospital of Inner Mongolia Medical University, Hohhot

The First Affiliated Hospital of Nanchang University, Nanchang

Jilin Cancer Hospital, Changchun

The First Hospital of China Medical University, Shenyang

Shanghai East Hospital Tongji University, Shanghai

Shanxi Provincial Cancer Hospital, Taiyuan

West China School of Medicine/West China Hospital of Sichuan University, Chengdu

Mianyang Central Hospital, Mianyang

Zhejiang University Cancer Hospital, Hangzhou

Fujian Cancer Hospital (Department of Hepatobiliary and Pancreatic Oncology /Phase I Ward), Fuzhou

Harbin Medical University Cancer Hospital (Gastroenterology Department 2nd Ward), Haerbin

Zhongshan Hospital of Fudan University (Hepatological Surgery Department), Shanghai

Zhongshan Hospital of Fudan University (Medical Oncology Department), Shanghai

Liaoning Cancer Hospital (Phase I Ward), Shenyang

Yantai Yuhuangding Hospital (Department of Medical Oncology, 1), Yantai

Sponsors
All Listed Sponsors
lead

Abbisko Therapeutics Co, Ltd

INDUSTRY

NCT05627063 - A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter